HIPERKOAGULOPATI PADA COVID-19

Abstract

Coronavirus Disease 2019 (COVID-19), originally named 2019-nCoV, is the first disease to be discovered in Wuhan, China. This disease is found as an outbreak of respiratory tract infection of unknown cause which may be caused by the SARS-CoV-2 virus or COVID-19. Symptoms of COVID-19 can include complaints of breathing, shortness of breath, coughing and fever. Hospitalized COVID-19 patients with severe symptoms are at risk for venous thromboembolism. Thromboembolic complications are an important problem in patients infected with COVID-19. In COVID-19 patients, laboratory abnormalities are found, including thrombocytopenia, increased D-dimers, prolonged prothrombin time, and disseminated intravascular coagulation. The data show that coagulation disorders, especially an increase in D-dimers and fibrinogen-degradation product (FDP), were found to be very high in pneumonia patients who died from COVID-19 infection. Inflammatory reactions occur in all organs of the body, damage to the microvascular system, causing abnormalities in the coagulation system manifested by vasculitis of small vessels and extensive micro thrombosis The most common parameters of abnormal coagulopathy in patients with COVID-19 infection are increased concentrations of D-dimer and FDP in severe infection DIC is a syndrome characterized by intravascular coagulation due to local damage that exacerbates coagulopathy and results in multi-organ failure. Research reports that the use of Arixta (Fondaparinux) as anticoagulant therapy in severely infected COVID-19 patients with coagulopathy has been shown to be effective and safe and there were no bleeding complications